Cabaletta Bio Stock (NASDAQ:CABA)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$3.03

52W Range

$2.61 - $26.35

50D Avg

$4.23

200D Avg

$10.60

Market Cap

$131.97M

Avg Vol (3M)

$965.39K

Beta

2.42

Div Yield

-

CABA Company Profile


Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

136

IPO Date

Oct 25, 2019

Website

CABA Performance


CABA Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-74.66M$-54.14M$-46.31M
Net Income$-67.67M$-51.81M$-45.53M
EBITDA$-73.23M$-54.14M$-46.31M
Basic EPS$-1.65$-2.41$-13.68
Diluted EPS$-1.65$-2.41$-13.68

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
PLRXPliant Therapeutics, Inc.
RVMDRevolution Medicines, Inc. Warrant
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
STOKStoke Therapeutics, Inc.
ALECAlector, Inc.
BDTXBlack Diamond Therapeutics, Inc.
BCELAtreca, Inc.
PASGPassage Bio, Inc.
ACLXArcellx, Inc.
ETNB89bio, Inc.
FIXXQ32 Bio Inc.
MDGLMadrigal Pharmaceuticals, Inc.